Evidence map›Paper›PMID 33058771›Full record

ArticleThe Lancet. Respiratory medicine2021

Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database.

Stefano Barco, Luca Valerio, Walter Ageno, Alexander T Cohen, Samuel Z Goldhaber, Beverley J Hunt, Alfonso Iorio, David Jimenez, Frederikus A Klok, Nils Kucher and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 4 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Review
  7. Review
  8. Article
  9. Initial management of intermediate- and high-risk pulmonary embolism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Review
  10. How patient profile and hospital setting drive pulmonary embolism treatment modality.Journal of vascular surgery. Venous and lymphatic disorders · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 9 countries.

Stefano BarcoCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Clinic of Angiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: stefano.barco@usz.ch.
Luca ValerioCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.
Walter AgenoDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Alexander T CohenDepartment of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Samuel Z GoldhaberDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Beverley J HuntSt Thomas' Hospital Thrombosis and Haemophilia Centre and Thrombosis and Vascular Biology Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Alfonso IorioDepartment of Health Research Methods, Evidence, and Impact, and Department of Medicine, McMaster University, Hamilton, ON, Canada.
David JimenezRespiratory Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBER Enfermedades Respiratorias, (CIBERES), Madrid, Spain.
Frederikus A KlokCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Netherlands.
Nils KucherClinic of Angiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Seyed Hamidreza MahmoudpourCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Institute for Medical Biostatistics, Epidemiology, and Informatics, University Medical Center Mainz, Mainz, Germany.
Saskia MiddeldorpDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Thomas MünzelCenter for Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; DZHK (German Center for Cardiovascular Research), partner site RhineMain, Mainz, Germany.
Vicky TagalakisCentre for Clinical Epidemiology of the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Aaron M WendelboeDepartment of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Stavros V KonstantinidesCenter for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece.
University Medical Center of the Johannes Gutenberg University Mainz · DEAmsterdam University Medical Centers · NLBrigham and Women's Hospital · USCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESDemocritus University of Thrace · GRGuy's and St Thomas' NHS Foundation Trust · GBImpact · CAJewish General Hospital · CALeiden University Medical Center · NLSt Thomas' Hospital · GBUniversity of Insubria · ITUniversity of Oklahoma Health Sciences Center · USUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary embolism (PE)-related mortality is decreasing in Europe. However, time trends in the USA and Canada remain uncertain because the most recent analyses of PE-related mortality were published in the early 2000s.

methodsFor this retrospective epidemiological study, we accessed medically certified vital registration data from the WHO Mortality Database (USA and Canada, 2000-17) and the Multiple Cause of Death database produced by the Division of Vital Statistics of the US Centers for Disease Control and Prevention (CDC; US, 2000-18). We investigated contemporary time trends in PE-related mortality in the USA and Canada and the prevalence of conditions contributing to PE-related mortality reported on the death certificates. We also estimated PE-related mortality by age group and sex. A subgroup analysis by race was performed for the USA.

findingsIn the USA, the age-standardised annual mortality rate (PE as the underlying cause) decreased from 6·0 deaths per 100 000 population (95% CI 5·9-6·1) in 2000 to 4·4 deaths per 100 000 population (4·3-4·5) in 2006. Thereafter, it continued to decrease to 4·1 deaths per 100 000 population (4·0-4·2) in women in 2017 and plateaued at 4·5 deaths per 100 000 population (4·4-4·7) in men in 2017. Among adults aged 25-64 years, it increased after 2006. The median age at death from PE decreased from 73 years to 68 years (2000-18). The prevalence of cancer, respiratory diseases, and infections as a contributing cause of PE-related death increased in all age categories from 2000 to 2018. The annual age-standardised PE-related mortality was consistently higher by up to 50% in Black individuals than in White individuals; these rates were approximately 50% higher in White individuals than in those of other races. In Canada, the annual age-standardised mortality rate from PE as the underlying cause of death decreased from 4·7 deaths per 100 000 population (4·4-5·0) in 2000 to 2·6 deaths per 100 000 population (2·4-2·8) in 2017; this decline slowed after 2006 across age groups and sexes.

interpretationAfter 2006, the initially decreasing PE-related mortality rates in North America progressively reached a plateau in Canada, while a rebound increase was observed among young and middle-aged adults in the USA. These findings parallel recent upward trends in mortality from other cardiovascular diseases and might reflect increasing inequalities in the exposure to risk factors and access to health care.

fundingNone.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsCanadaCause of DeathChildChild, PreschoolDatabases as TopicFemaleHumansInfantInfant, NewbornMaleMiddle Aged

Identifiers

PMID33058771
PMCPMC7550106
OpenAlexW3091941561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.